duvelisib
duvelisib: 7 clinical trials tracked.
duvelisib evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about duvelisib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Clinical Trial Registry Records (7)
A Phase II Study of Duvelisib Maintenance After First-Line Therapy for Peripheral T-Cell Lymphoma
Primary endpoint: Progression free survival
A Multicentre, Open-label, Phase 3, Randomised Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Primary endpoint: Progression-free Survival (PFS) as assessed by the Independent Review Committee (IRC)
A Phase I Study With an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and Sézary Syndrome (SS)
Primary endpoint: Maximum tolerated dose or recommended phase II dose (RP2D)
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
Primary endpoint: Complete remission (CR) rate
A Phase 1b/2 Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Primary endpoint: Number of participants with adverse events
An Open-Label, Single-Arm, Multicenter Phase 1 Study Evaluating the Safety and Pharmacokinetics of Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
Primary endpoint: Number of participants reporting Treatment-emergent Adverse Events
A Phase 1b/2 Study of IPI-145 in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia.
Primary endpoint: Number of Patients Who Experienced a Dose Limiting Toxicity (DLT) During Phase I